Feasibility of hypomethylating agents followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome. (Q53429887)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21478916%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

title

Feasibility of hypomethylating agents followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21478916%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21478916%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

author name string

D-Y Kim

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21478916%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

J-H Lee

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21478916%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Y-H Park

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21478916%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

J-H Lee

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21478916%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

S-D Kim

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21478916%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Y Choi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21478916%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

S-B Lee

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21478916%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

K-H Lee

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21478916%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

S Y Ahn

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21478916%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Y-S Lee

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21478916%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

M Seol

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21478916%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Y-A Kang

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21478916%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

M Jeon

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21478916%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Y-J Lee

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21478916%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

K-H Lee

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21478916%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

language of work or name

English

0 references

publication date

11 April 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21478916%20AND%20SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

28 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21478916%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

volume

47

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21478916%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21478916%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

page(s)

374-379

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21478916%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/bmt.2011.86

28 January 2020

exact match

0 references

cites work

Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.86

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.86

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.86

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.86

Identification of a fibrin-independent platelet contractile mechanism regulating primary hemostasis and thrombus growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.86

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.86

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.86

Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.86

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.86

Targeted therapies in myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.86

The evolution of hematopoietic SCT in myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.86

Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.86

Methylation profiling in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.86

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.86

Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.86

5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.86

Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.86

Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: prognostic significance of pre-transplant IPSS score and comorbidity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.86

MODULATION OF HLA-DR ANTIGENS EXPRESSION IN HUMAN MYELOID LEUKAEMIA CELLS BY CYTARABINE AND 5-AZA-2'-DEOXYCYTIDINE

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.86

Continuous infusion of low-dose 5-Aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.86